The Danish biotech group will report its full year results for 2009/10 on 22 June – and it now expects to report revenue of around DKK13.65bn, up from around DKK13bn it said it expected at the end of Q3.
Danisco’s EBIT margin milestone for FY2009/10 was 12.5 percent (before bio chemicals project. This has already been met. EBIT is expected to be at least DKK1700m.